The Latest Analyst Ratings for IGM Biosciences
Portfolio Pulse from Benzinga Insights
IGM Biosciences (NASDAQ:IGMS) has received various analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, and 2 indifferent. Over the past 3 months, 5 analysts have offered 12-month price targets for IGM Biosciences, with an average price target of $20.4, a 2.86% decrease from the previous average price target of $21.00.
August 17, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
IGM Biosciences has received mixed analyst ratings in the last quarter, with an average price target of $20.4, a 2.86% decrease from the previous average price target.
The mixed analyst ratings indicate uncertainty about the company's performance. The decrease in the average price target suggests that analysts have slightly lowered their expectations for the stock, which could potentially impact investor sentiment and the stock's price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100